Narita M, Kurihara T, Usami M, Honda M
Department of Internal Medicine, Sumitomo Hospital.
Kaku Igaku. 1994 Dec;31(12):1465-76.
To investigate the characteristics of fatty acid metabolism in hypertrophic cardiomyopathy (HCM), we performed myocardial imaging with 123I-iodophenyl-3-methylpentadecanoic acid (BMIPP) in 24 patients with HCM, 13 patients with hypertensive hypertrophy (HT) and 10 normal subjects. Rest myocardial imaging with 123I-BMIPP was obtained at 20 minutes and 3 hours after 123I-BMIPP injection. Rest 201Tl imaging was also performed. In addition to ordinary tomography, whole body imaging was performed to calculate % Uptake (percentage of cardiac uptake of the isotope to total injected dose). As global indexes of fatty acid metabolism, we calculated two parameters; 1) Uptake Ratio (%Uptake of 123I-BMIPP normalized by myocardial perfusion) and 2) WOR (percent reduction of myocardial 123I-BMIPP within 3 hours). Regional abnormality was evaluated by visual assessment of ordinary tomograms and by BMIPP/T1 map. BMIPP/T1 map was made from Bull's-eye maps of 123I-BMIPP and 201Tl, and it represented 123I-BMIPP uptake normalized by myocardial perfusion of each pixel which constructed the image. %Uptake of 123I-BMIPP was not different among three groups. But Uptake Ratio was significantly (p < 0.001) different among three groups; normal (1.13 +/- 0.08) > HT (1.03 +/- 0.08) > HCM (0.87 +/- 0.09). WOR of 123I-BMIPP was accelerated in HCM (12.7 +/- 4.7%) and HT (10.2 +/- 2.9%) comparing with that in normal (5.1 +/- 3.1%) (p < 0.01). In patients with HCM, by visual assessment, regional abnormality of 123I-BMIPP distribution was found in 17 of 24 patients (71%) including 3 patients with equivocal abnormality. But in patients with HT, only equivocal abnormality was observed in 23%. In BMIPP/T1 map, abnormality was observed in 92% of HCM and 8% of HT. Although global myocardial fatty acid metabolism was equally disturbed both in HCM and HT, regional abnormality of fatty acid metabolism was observed preferentially in HCM. This indicated myocardial fatty acid metabolism was not identical between HCM and HT.
为了研究肥厚型心肌病(HCM)患者脂肪酸代谢的特征,我们对24例HCM患者、13例高血压性心肌肥厚(HT)患者和10名正常受试者进行了¹²³I-碘苯基-3-甲基十五烷酸(BMIPP)心肌显像。在注射¹²³I-BMIPP后20分钟和3小时进行静息心肌显像。同时也进行静息²⁰¹Tl显像。除了普通断层显像外,还进行了全身显像以计算摄取百分比(同位素心脏摄取量占总注射剂量的百分比)。作为脂肪酸代谢的整体指标,我们计算了两个参数:1)摄取率(¹²³I-BMIPP摄取百分比经心肌灌注校正)和2)WOR(3小时内心肌¹²³I-BMIPP减少百分比)。通过对普通断层显像的视觉评估以及BMIPP/T1图评估区域异常情况。BMIPP/T1图由¹²³I-BMIPP和²⁰¹Tl的心形图制成,它表示每个构成图像像素的¹²³I-BMIPP摄取量经心肌灌注校正后的值。三组间¹²³I-BMIPP的摄取百分比无差异。但摄取率在三组间有显著差异(p<0.001);正常组(1.13±0.08)>HT组(1.03±0.08)>HCM组(0.87±0.09)。与正常组(5.1±3.1%)相比,HCM组(12.7±4.7%)和HT组(10.2±2.9%)的¹²³I-BMIPP的WOR加快(p<0.01)。在HCM患者中,通过视觉评估,24例患者中有17例(71%)发现¹²³I-BMIPP分布存在区域异常,其中3例为可疑异常。但在HT患者中,仅23%观察到可疑异常。在BMIPP/T1图中,92%的HCM患者和8%的HT患者存在异常。虽然HCM和HT患者的整体心肌脂肪酸代谢均受到同等程度的干扰,但脂肪酸代谢的区域异常在HCM患者中更为常见。这表明HCM和HT患者的心肌脂肪酸代谢并不相同。